ABIVAX Société Anonyme (NASDAQ:ABVX) Sees Unusually-High Trading Volume

ABIVAX Société Anonyme (NASDAQ:ABVX) shares saw unusually-high trading volume on Friday . Approximately 50,431 shares were traded during trading, a decline of 40% from the previous session’s volume of 83,771 shares.The stock last traded at $11.06 and had previously closed at $11.02.

Analyst Ratings Changes

ABVX has been the topic of a number of recent research reports. BTIG Research started coverage on ABIVAX Société Anonyme in a report on Monday, May 20th. They issued a “buy” rating and a $43.00 target price on the stock. Guggenheim began coverage on ABIVAX Société Anonyme in a report on Monday, April 29th. They set a “buy” rating and a $50.00 price objective on the stock. Laidlaw began coverage on shares of ABIVAX Société Anonyme in a research note on Monday, July 29th. They set a “buy” rating and a $48.00 price objective for the company. Finally, Piper Sandler began coverage on shares of ABIVAX Société Anonyme in a research report on Monday, April 29th. They issued an “overweight” rating and a $42.00 target price on the stock. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, ABIVAX Société Anonyme currently has an average rating of “Moderate Buy” and a consensus price target of $36.50.

ABIVAX Société Anonyme Stock Performance

The company has a 50 day simple moving average of $12.68 and a two-hundred day simple moving average of $13.57. The company has a debt-to-equity ratio of 0.23, a quick ratio of 4.08 and a current ratio of 4.08.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets acquired a new stake in shares of ABIVAX Société Anonyme during the 1st quarter valued at $81,000. Capstone Investment Advisors LLC purchased a new stake in shares of ABIVAX Société Anonyme during the fourth quarter worth $618,000. Ghisallo Capital Management LLC acquired a new stake in ABIVAX Société Anonyme during the fourth quarter valued at $642,000. Kennedy Capital Management LLC grew its stake in ABIVAX Société Anonyme by 35.3% in the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock valued at $1,718,000 after purchasing an additional 31,331 shares in the last quarter. Finally, Rosalind Advisors Inc. purchased a new position in ABIVAX Société Anonyme in the first quarter valued at about $5,411,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.